Invex Therapeutics Ltd (ASX:IXC)

Invex Therapeutics Income Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Other Revenue	1.21	1.21	0.46	0.18	-	-
Revenue	1.21	1.21	0.46	0.18	-	-
Revenue Growth (YoY)	9856.93%	164.06%	151.90%	-	-	-
Gross Profit	1.21	1.21	0.46	0.18	-	-
Selling, General & Admin	0.92	1.17	1.12	0.9	0.74	0.67
Research & Development	0.37	2.04	7.4	2.96	1.14	1.59
Operating Expenses	1.33	3.35	9.01	4.22	2.44	3.25
Operating Income	-0.12	-2.13	-8.55	-4.03	-2.44	-3.25
Interest & Investment Income	0.23	0.49	0.8	0.08	0.16	0.17
Other Non Operating Income (Expenses)	-0	-	-	-	0	-0.16
EBT Excluding Unusual Items	0.11	-1.64	-7.75	-3.95	-2.28	-3.24
Asset Writedown	-	-	-	-	-	-0.12
Pretax Income	0.11	-1.64	-7.75	-3.95	-2.28	-3.36
Net Income	0.11	-1.64	-7.75	-3.95	-2.28	-3.36
Net Income to Common	0.11	-1.64	-7.75	-3.95	-2.28	-3.36
Shares Outstanding (Basic)	76	75	75	75	75	56
Shares Outstanding (Diluted)	76	75	75	75	75	56
Shares Change (YoY)	0.62%	0.19%	0.02%	0.03%	33.77%	138.02%
EPS (Basic)	0.00	-0.02	-0.10	-0.05	-0.03	-0.06
EPS (Diluted)	0.00	-0.02	-0.10	-0.05	-0.03	-0.06
Gross Margin	100.00%	100.00%	100.00%	100.00%	-	-
Operating Margin	-9.61%	-176.00%	-1861.73%	-2212.89%	-	-
Profit Margin	9.43%	-135.43%	-1688.11%	-2169.06%	-	-
EBIT	-0.12	-2.13	-8.55	-4.03	-2.44	-3.25
EBIT Margin	-9.61%	-176.00%	-	-	-	-

Updated Feb 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.